1
Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients
Condition(s):Triple Negative Breast CancerLast Updated:December 5, 2019Recruiting
Triple-negative Breast Cancer: 864 Clinical Trials, Page 1 of 87
Hide Studies Not Open or Pending
2
Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients
Condition(s):Triple Negative Breast CancerLast Updated:November 18, 2019Recruiting
3
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Condition(s):Triple Negative Breast CancerLast Updated:July 7, 2020Completed
4
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer
Condition(s):Triple-Negative Breast CancerLast Updated:February 6, 2018Unknown status
5
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
Condition(s):Triple Negative Breast CancerLast Updated:June 18, 2020Recruiting
6
TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer
Condition(s):Triple Negative Breast CancerLast Updated:September 9, 2020Not yet recruiting
7
Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients
Condition(s):Triple Negative Breast CancerLast Updated:July 22, 2020Not yet recruiting
8
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Condition(s):Triple-negative Breast CancerLast Updated:March 24, 2020Completed
9
Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC
Condition(s):Triple Negative Breast CancerLast Updated:April 29, 2020Not yet recruiting
10
TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Condition(s):Triple-Negative Breast CancerLast Updated:September 24, 2019Recruiting